SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US ETFDetailed Quotes

XBI SPDR S&P Biotech ETF

Watchlist

99.310
-0.310-0.31%

Close Dec 2 16:00 ET

99.640High98.540Low

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
Kevin Travers16:25 ET
Gilead Sciences Ticks Upward for the Eight Consecutive Session
Seeking Alpha14:28 ET
Looking Into Natera's Recent Short Interest
Benzinga12:45 ET
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
Benzinga11:19 ET
December Starts With a Mixed Market | Live Stock
Kevin Travers11:13 ET
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
BenzingaDec 1 10:48 ET

Comments

topcing

Nov 4 21:29

$SPDR S&P Biotech ETF (XBI.US)$ yea

股勇者

Oct 25 10:17

$SPDR S&P Biotech ETF (XBI.US)$ 100 month end? ok?

Bellaah

Sep 11 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

Moomoo Learn

Sep 6 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

CPI hits 3-year low: How will it sway the Fed rate decision?

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?